Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Canatu, Webcast, Q2'26

By Inderes8/25/2026, 9:00 AM
Canatu

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maximilian Slawinski
00:01 - 17:27

Hello, everybody. Ladies and gentlemen, investors. Let me briefly introduce myself, as we are meeting in many cases for the first time. My name is Dr. Maximilian Slawinski, and I have been the new CEO of Canatu since May. I have been part of the semiconductor, automotive, and new energy industries. For almost two decades. My first 100 days at Canatu have progressed, and they have just confirmed my hopes to join a company leading in one of the most emerging segments in the entire tech industry. We will present today, beside our half-year financial report results, some remarkable achievements the company has been able to perform within the last 100 days. You most probably heard already yesterday about our great news of our recent reactor order from a semiconductor customer, the first since our SPAC, the first since almost three years. And most importantly, looking ahead, we are introducing our new plan to target more than €100 million in revenue by 2030. We will furthermore present today our Polaris Program. We have already published our management reorganization, and I will go a little bit deeper into this today. We will present our new strategy towards targeting more than €100 million in revenue by 2030, based on focused and fast execution within organically strong growing and profitable markets. We are also presenting our vision for 2035, and a third pillar of our Polaris Program will explain our implemented cost measures, securing a disciplined cash management with a streamlined Canatu, including headcount adjustments. I believe today's presented achievements are a testament. What is Canatu capable of? What the Canatu team is able to improve and transform in a short amount of time is a result of an energized team willing to win. I hope you will come to the same conclusion as me, experiencing this company performing at a pivotal moment for future success. So let's start. Where does Canatu stand today? Are we world class? I think Canatu has proven already in the past that we are able to industrialize products and to mass-manufacture them based on our dry deposition technology. And I think good examples are the approximately 1 million sensors we delivered in the automotive and defense industry, as well as more than 5,000 inspection membranes, fault-free since 2021. This is a strong foundation. We are also close to entering new, promising, and fast-growing markets in particular. Of course, the CNT pellicle market, as well as ADAS for advanced ADAS systems. Canatu is very strong in industrializing the property tuning of CNTs. And this property tuning is resulting in physical properties responding to the most important challenges of the industries we are targeting. And last but not least, Canatu has established very deep and long-term relationships with global leading companies, which I have to say is in that magnitude remarkable for a company compared to Canatu's size. Here, the company is already world-class. Nevertheless, that is not enough, and Canatu needs to improve. Canatu needs, in particular, to improve its execution to hit its commercial ambitions. And therefore, we need to be more focused. We will present today a strategy reducing the complexity of our company and our operations. We had in the past too many balls in the air and we have to catch the most valuable ones. We have to invest all our resources into scalable product roadmap execution instead of engineering projects. Canatu needs to be in the future more customer-focused and less research-driven. And last but not least, the allocation of our development resources needs to be based more on commercial metrics. Therefore, we introduce the Polaris Program. This is our transformation program for the company. We have already published the changes in governance. We now have a five-person executive management team fully staffed from next week onwards. We recruited Bernd Meier, our CMO, and Walter Braun, our CTO, two experienced international executives with a strong track record in our target industries. We changed the old New Business Development Department into a Fellow office with a stronger focus on our IP strategy. We established new departments to support top-line growth, in particular business development to tackle the OEMs of our end markets. The OEMs of our end markets, as well as new product management functions in the business units, will accelerate time to revenue as well as focus more strongly on productization. Project management will be reintegrated into R&D in the future. And last but not least, the business units will have the project ownership of our most important R&D projects. With respect to the strategy, we are clarifying our business models. The Semiconductor Business Unit will remain a product business in the inspection product line in the semiconductor manufacturing segment. So, for the bigger part of the term, we will focus on being an equipment and technology provider. The former Automotive Business Unit, which is now the Robotics, Mobility, and Defense Business Unit, will be a pure product business with a clear focus on strongly growing markets in automotive, robotics, and defense. The medical business unit remains a product business. We have prioritized our roadmap based on the value we deliver. A strong indicator for this is the euro per square centimeter value we introduced to evaluate the value our products deliver, and we have stopped selling engineering services. Regarding the OpEx adjustment. We are planning to reduce the headcount by up to 17 full-time employees. We will limit our yearly CAPEX until 2030 to less than 6 million per year. We are introducing the revenue per employee in 2030 as a new KPI, and we will discontinue low-value R&D projects. In the first 100 days. We started to successfully sharpen our company's strategy. Of course, we are an innovation leader building a structurally high-margin business. We will focus in the future more strongly on scalable top-line growth. What remains is our commitment to achieve more than 100 million in revenue by 2030, and we anticipate our divisions to grow by more than 20% per year. We target a CAGR of more than 20% until 2035. Let me shortly talk about our executive leadership team. The company's leadership has been restructured. The company is now led by a five-person executive management team. We have added Walter Braun and Bernd Meier to the team, two very experienced executives from the semiconductor equipment, semiconductor device, and robotics industries. I strongly believe that their experience, their track record, and their management skills will improve the company significantly. I also strongly believe that the newly introduced matrix structure within Canatu will increase our resource allocation and resource efficiency and our product and business focus. The business units will in the future be internal customers within the company, in particular owning the business cases and the business unit strategies. While the operational leadership will sustain the executive management and the business unit leaders in their daily work. What remains is, of course, our core Canatu, whose DNA is our dry deposition technology. It is a strong competitive moat, and as mentioned, we have already proven in the past with about 1 million sensors delivered in the automotive and defense markets, as well as more than 5,000 inspection membranes, that we are able to industrialize and produce differentiating products based on that technology. Across the three business units, we work with different business models, including manufacturing partners, enabling us to integrate up to the OEM level. Our backbone remains our strong patent portfolio, where we will even more aggressively grow the number of patents and families in the future. It also serves as a backbone, enabling us to commercialize royalties and fees in the future. Our three business units are tackling markets from different directions. I would say these are very hot markets in our society, for sure. The most discussed market, and perhaps the most interesting, is the artificial intelligence market. As you know, artificial intelligence is not working without memories, GPUs, and CPUs. And our CNT technology is a big part in manufacturing these devices and boosting the manufacturing of these devices in the future. When we think about humanoid robots, we also have to talk about actuators and sensors, and we are quite advanced in LiDAR and other solutions, as well as tactile sensors. This is an example when you include humanoid AI. This illustrates how two different business units at Canatu tackle the same end market. A similar situation exists in autonomous driving. We talk a lot about ADAS, but of course, an autonomous car also needs memories, GPUs, and CPUs. Also here again, two business units are part of the same end market with different positions in the supply chain. We conduct successful business already today in the defense market, and we target to expand this; also, here, beside our RMD business unit, GPUs and memories will be important in future defense solutions. Canatu is, of course, targeting to be part of the semiconductor manufacturing industry. And last but not least, medical diagnostics. Here we are, even integrating into a full solution provider. And again, semiconductors will help in the analysis of diagnostics and in improving their efficiency. So it shows our business units deliver from different perspectives to the most important end markets of society without increasing the complexity of Canatu. Let me briefly explain the just-mentioned disciplined portfolio prioritization. I mentioned in the beginning that we will allocate our future development resources, in particular with respect to commercial indicators. Here you see an example of how we will prioritize our product roadmap in the future. You see that we fully focus on the highest CNT per square centimeter value we identified for our most promising products, and on the other side, also focus strongly on high-growing end markets. As you can see, we expect to deliver extremely high value in the hormone testing market as well. We already proved our ability to deliver in the inspection filters, while in the RMD market we have an even wider portfolio, a broader end-market spectrum, and particularly strong organically growing markets. When we think about robotics and industrial sensing. About our markets. I know it has been evaluated many times, and here I want to highlight, first of all, the semiconductor market. On the right side, you see the advanced-node market starting from seven nanometer. And below in the structure, you see that the two-nanometer and below segment is just a minority part today, but it will dominate the Advanced-Node market in the future. And here in particular is a strong opportunity for CNT pellicles, as these structures demand high wattage and a higher number of layers in the manufacturing. It is a small market today, but it is projected to grow with a 25% CAGR over the next ten years. A very strong market in that segment in the future, underlining our growth ambitions not only until 2030, but even until 2035. A similar picture for the autonomous driving market. The ADAS market is already big today, but dominated by ADAS level one and two. Just starting is ADAS level three and four. While our heater solutions might be an add-on in ADAS level one and two, they become a crucial aspect to increase the safety of ADAS level three and beyond. And again, we are talking about a segment growing with almost 20% CAGR over the next ten years. Again, underlining the just-mentioned long-term growth ambition. How does this strategy translate into shareholder value? We have drafted the most important milestones we achieved in the past in the RMD and semiconductor segments. And we just achieved another very important milestone yesterday with our third reactor order. But of course, the next important step in the semiconductor industry will be the qualification of the EUV pellicles at the device site. That will be the defining moment. The dry deposition technology, the CNT, based on the Canatu technology, will enter the end market. And this we will have to achieve with our customers as a next big step in the medical business. We will soon start the FDA pathway. And of course, in the RMD business, we will finish the development of the ADAS heaters and will in particular roll them out in the most advanced autonomous driving systems. With that, I will hand over now to Mikko for a deeper dive into the financials.

Mikko Vesterinen
17:29 - 25:15

Thank you, Max. So let's start with the financial highlights of the first half. Our revenue was 4.2 million, which is a low number that we acknowledge. But at the same time, we want to emphasize that our long-term potential and our long-term pipeline are intact. We did not lose any business to our competitors during the first half, and our competitive position remains very strong. Secondly, our gross margin remains at a good level, and we take this as evidence of the inherently good profitability of our business. We just need to scale up the revenue. And thirdly, what we want to emphasize is our strong balance sheet; it is debt-free. Our cash position remains good, and these are very valuable assets in the growth phase and in the industries we are operating in connection with the strategy work. In line with what Max just described, we also updated our financial targets. So we continue to aim at more than 500 million in revenue in 2030. But given the markets where we are operating, we are confident that if we reach this, we should target also high continued growth thereafter. Therefore, we have a target of reaching a minimum 20% CAGR from 2030 to 2035. Additionally, given the. The decisions that we made during the start of this process, i.e. that we will operate with the reactor model in the EUV pellicle business, and that we will focus on scalable product businesses elsewhere. We are confident that we can make this growth happen in a very resource- and capital-efficient way. And that means that we are targeting to reach an average revenue per employee of over €400,000 in 2030. And we do see that this can be done with less than 6 million euros of average annual CAPEX from next year onwards. This year, as we have previously stated, will be a peak year of CAPEX for Canatu. We currently see that the CAPEX this year will be a maximum of €13 million. So, less than previously anticipated. And this is also a reflection of the change in our strategy. And the reason why we are picking this year is the investments in the second factory and in the EU. We are deploying the EUV pellicle scanner, which are exceptional investments for a company like Canatu. Then let's dive a bit deeper into the first half figures. Semiconductor revenue was 4.0 million, and that was a result of a lack of new reactor orders. But as announced yesterday, we were able to close one new order, which is a very big and important milestone. And the second big factor behind this semiconductor revenue was one major inspection membrane customer who is working down their high inventory levels. It is not that our competitive position in inspection membranes has changed. It remains very strong, and we expect that the demand for these membranes will pick up again once the inventory levels get back to a normal level. This is also a reflection of the fact that our product performance has been better than anticipated. It has a longer lifetime than what we and the customer originally expected; in robotics, medical, and diagnostics, our revenue in the first half was 3.6 million, and that was mostly a result of completed engineering projects. And there we had the potential to make even higher revenue. However. Due to the decision to refocus our resources to the areas and efforts which we believe will create the most shareholder value in the longer term, we did not continue some projects there. And that is kind of a short-term pain. We were trading that for longer-term margin gains. Gross margins remained good, although they decreased on a year-on-year basis. But that was a reflection of changes in the revenue mix in terms of the profitability potential of these different businesses. There are no changes. Everything remains good. That said, operating expenses did continue to grow in the first half. And that was driven mostly by continued headcount growth. But now, as Maximilian Slawinski noted, we are also taking measures on that front. At the same time, we also increased our investments in R&D activities, especially on the medical side, and these new premises—meaning our new factory—also brought some new costs into our P&L; investments, as mentioned, were high in the first half and will remain high this year. But mostly they are now done. So. So first-half investments in capital expenditure amounted to 10.5 million. With these investments, we have significantly expanded our capacity and also increased our quality control capabilities in a very meaningful way. The balance sheet cash position remains strong, as I mentioned. Then, let us look at the outlook for this year. As we announced yesterday in connection with this reactor order, we published preliminary information. Despite the reactor order, we do see that this year's revenue will decline significantly compared to the previous year's 15.6 million. Back then, our long-term potential remains intact in all business areas. This decline this year is a result of things progressing. Of course, not everything is in our hands. It depends to some extent on our customers and further on their customers. That is beyond our control. Then, obviously, we need to improve our own execution as well. That is what Max already highlighted. Furthermore, as mentioned, we have made some conscious decisions to discontinue certain businesses and operations, which will bring some short-term pain this year. But I think that is it from the financials. Now I hand over back to Max to conclude. Yes.

Maximilian Slawinski
25:17 - 26:25

So to conclude. We presented our Polaris Program today, which includes 12 major changes we have implemented in the last 100 days within our company. This will be a foundation for the future success. I strongly believe the company will focus even more on profitable top-line growth, underlined by the newly introduced CMO Department. On the other side, we will improve our R&D execution efficiency with a CTO Department as project management lead and the business units as project owners. With these measures, I am confident that Canatu will succeed in building a 100 million plus revenue company by 2030, with a vision to reach levels up to 300 million by 2035, based on the just-mentioned 20% plus CAGR from 2030 onwards. Thank you very much.

Mikko Vesterinen
26:30 - 26:33

Now it's time for questions from the audience.

Unknown 1
26:35 - 26:47

Hi, it's from DNB Carnegie. Maybe first about the discontinued businesses and operations. Can you open up a little bit? What businesses have now been discontinued, and what was their revenue impact, for example, last year?

Maximilian Slawinski
26:50 - 27:38

The businesses we discontinued were in part projects where we sold engineering hours. Engagements where we sold a kind of engineering hours. So a project-based business where our engineers were permanently executing projects together with partners who were paying for it. But of course, it had a lot of opportunity costs. So. These engineers could not focus on accelerating product roadmap execution. We stopped that activity to be on time or even faster with finishing our product developments and being able to hand them over properly to our manufacturing, as we were not optimistic about the scalability of that approach. About the financial impact. I'll leave it to Mikko.

Mikko Vesterinen
27:40 - 28:06

As you can see. As mentioned, the RMD business is where most of these activities reside, including those that have been stopped. It still grew very well in the first half with these engineering projects. But obviously the revenue mix there will be different going forward.

Unknown 1
28:08 - 28:24

All right, now we know the first reactor order has come in, but how about this? Another reactor customer. And there is the SAT. Approvals are still ongoing. Can you say anything about the situation, how it is developing at the moment?

Maximilian Slawinski
28:28 - 29:16

So of course, it is not fully in our hands. And at the end, it is part of a bigger supply chain beyond Canatu to have that final approval. We also have to consider that due to the high loading situation in the semiconductor device part, the resources to engineer new technologies are very limited at the moment, because a bigger part of the industry is executing its order book, and that is typically not the best time to implement new technologies. Nevertheless, in the 100 days I have been here. I have seen reasonable progress in that, making me optimistic about it. We will conclude that in a reasonable amount of time.

Unknown 1
29:19 - 29:28

What kind of expectations do you have for the two FSD reactors, and when will those start to generate meaningful recurring revenue for Canatu?

Maximilian Slawinski
29:28 - 30:14

Yeah. So first of all, when a customer orders a secondary reactor, that is a strong sign. That is really a commitment. That makes a big difference. From my point of view, having just one reactor is a testing phase. So, obviously, that is already a strong indicator of the progress our partner is doing in that segment. At the end, of course, it depends on their customer with respect to the recurring revenue. But from my point of view, that is then a matter of time, but the fact that they are already expanding their manufacturing capacity is, of course, a very good indicator. And obviously there is strong confidence in the near-term market introduction, underscored by that order.

Unknown 1
30:16 - 30:29

And how do you see the use of CNT pellicles in low-NA productions? Now you were mentioning that two-nanometer is the most important one for me.

Maximilian Slawinski
30:29 - 32:30

There is a trade-off. So you have the wattage of the UV light source, you have the numerical aperture. And you also have to think about the number of layers per wafer. So. And there are different ways to realize advanced structures. We have to take into account that this is also technically possible, for example, with a significantly larger number of layers per wafer to have, even in today's standard technologies with normal numerical apertures and lower wattage, these advanced structures; and at the end, what the Canatu technology or what the CNT pellicles do is improve the manufacturing yield, which, for example, would also be important when you have more layers under today's numerical apertures because the yield costs become higher when the number of layers increases. And what CNT compared to compounds is advanced is the nature of being a pure carbon material. And ultimately, the atomic structure of CNT is similar to diamond. And that is the most robust material on the planet. And that is of course the promise of CNT to be an optically superior solution. And from the robustness, we move to advanced solutions. Today's pellicle standards are metal silicides. But as it is with the change of standards in the semiconductor industry, when you look in the past, it is typically about a decade. It is a gradual process and does not happen overnight. But if it is happening and if it is proven, it goes pretty fast. You. You have. You can. There are many examples in the past, for example, like the switch from DUV to EUV. By the way, when you look at how long ASML worked on EUV until it finally became a business, that was almost three decades, if I am not wrong. And of course, that patience is always needed when you are in the semiconductor business. But of course, a second reactor order from a customer is a very, very big commitment. And the company seems to be very, very confident.

Unknown 1
32:31 - 32:41

Your competitors have also announced some pellicle production of their own. So how do you see Canatu's competitive position has developed this year?

Maximilian Slawinski
32:44 - 33:18

With the second reactor order from FSC. Good. And that there are more companies working on CNT is first of all, good. That is in Canatu's interest that not just one company from Finland, but a larger number of companies are working on the same material class, Carbon Nanotube, compared to our competitors. I think in particular in tuning the properties which finally result in the optics and reliability. Our dry deposition technology is pretty advanced. So I think we have here a strong technological moat.

Unknown 1
33:20 - 33:35

You no longer provide a long-term EBIT margin target as you did previously. But can you provide any insight regarding your ambition level for the long term? Is it a similar kind of profitability that you were targeting before, or is it higher or lower?

Mikko Vesterinen
33:38 - 34:27

I think what we want to say is that at this point of the growth trajectory, we need to focus on revenue growth. That is the key thing. Our business remains very profitable, as evidenced by the gross margins. So if we are able to scale the top line, this will be a highly profitable company. There is no doubt about that. And also, I think you can use this new target of reaching €400,000 revenue per employee as an indication of our profitability because that is a direct proxy of our cost base. It is driven by this number of employees.

Unknown 1
34:27 - 34:28

All right. Thank you.

Walter Braun
34:33 - 34:55

Hi. Walter Braun from Danske Bank. Thanks for the presentation. A few questions as well. First, you state quite clearly, I think, that you focus now on selling reactors only in the semiconductor segment. So what led you to choose this route compared to the previous dual-track approach?

Maximilian Slawinski
34:58 - 35:58

I believe. For Canatu, it is favorable and also for its customers. If we choose a path and a business model, we increase the likelihood of making dry deposition the standard CNT manufacturing technology. And with that decision, we are more or less opening, via our reactor technology and the IP behind it, global access to this. Yeah. In the alternative scenario, if we were to produce EUV pellicles, we would become a competitor to companies that are currently in this business model and would otherwise become our potential customers. And with that, I'm pretty sure we increase the likelihood to make our technology a standard in this and our business model. So a combination of reactor sales and, of course, recurring revenues, I think will pay off if it is a standard in particular, and it is the basis for that decision. Of course, it also requires less CAPEX. No doubt about that.

Walter Braun
35:59 - 36:12

Okay. Thank you. And relating to that, do you know if your competitors are all selling pellicles directly, or are some of them selling reactors?

Maximilian Slawinski
36:14 - 36:27

I wouldn't know of any reactor supplier producing membranes for pellicles. I think the companies I have met are integrated up to the pellicle level.

Walter Braun
36:28 - 36:56

Okay. Thank you. Then also a question on the second customer and why they haven't accepted the reactor yet. So, basically, is there something wrong? It is not that they are unhappy with the customer; are they just not going to accept it until they need it? What is your read on the situation?

Maximilian Slawinski
37:03 - 37:46

As mentioned, first of all, each customer has different resources investing into a qualification of a new technology. And in particular, if a customer is busy in its operations and the order book is extremely large, that can easily prolong these kinds of processes. No doubt, our reactor technology is pretty new in the industry. And there is a lot to learn also via our customers, which then needs to be addressed and achieved together with the customers with respect to the parameter output. But I am very confident, as mentioned, that this will finally succeed. It's only a matter of time.

Walter Braun
37:49 - 38:12

Okay. Thank you. And one last question, at least for now. Was there any recurring revenue in each one? And what is your expectation on the recurring revenues going forward compared to the reactor price? And how much are you selling the reactors for now?

Mikko Vesterinen
38:15 - 38:55

That is many questions in one, but regarding the recurring revenues, what I think you are referring to as what we get from reactors is still significantly in the future. Of course, we are getting some recurring revenues when we sell services and some consumables for these reactors. But of course, the big thing will be. Then, when these pellicles are taken into mass production. And what was the other question?

Unknown 2
38:57 - 39:00

How much are you selling the reactors for?

Mikko Vesterinen
39:01 - 39:03

We still do not disclose that.

Unknown 3
39:08 - 39:35

Good afternoon, it's DNB Carnegie Investment Bank AB. A couple of questions also from me. First, I would like to return to the question which has been discussed already, which is the site acceptance test for the second manufacturing tool. You mentioned that you have made progress towards getting it accepted. What exactly have you achieved and what have you completed?

Maximilian Slawinski
39:38 - 39:59

So, the site acceptance tests are, of course, at a customer site. By yourself, I mean where the reactor is located. These are connected to a list of parameters that have to be achieved, where we have made progress. We have been able to successfully meet some parameters that were not previously achieved.

Unknown 3
40:00 - 40:11

Is there anything on your side that still needs to be done? Have you completed your part of the work that you can do in this timeframe?

Maximilian Slawinski
40:13 - 40:46

Of course, these site acceptance criteria are the output of the equipment, and what the equipment produces depends heavily on where it is located, for example, in which cleanroom, under which conditions, and how it is operated. Ultimately, all these criteria are the result of a combined effort. I believe it is difficult to isolate these specific criteria. This is a pure responsibility of Canatu or a pure responsibility of its customer. It is always a joint effort.

Unknown 3
40:48 - 41:10

All right. So if it's a joint effort and you are basically ready to do your part and have done so in the process, does it mean that the customer just doesn't feel the urgency to go through with the site acceptance test because there is no pressure for them to get the production running?

Maximilian Slawinski
41:12 - 43:15

When we think about what the pellicles in general are for, they are ultimately improving the yield of an existing manufacturing process. That means there is, for example, no hard time-based milestone where, with a change to a new technology, you could not start production without pellicles, for example. Whether it is metal silicides or CNT. It's not that the. The pellicle itself is the enabler to achieve, let's say, two nanometers. It is increasing the manufacturing output. I can also understand from my experience in semiconductor device companies when you ramp up a new generation with the lowest possible complexity, for example, by leaving out pellicles in total at the beginning, and then working in a second step on improving the yield. But yes, the customers have the option to decide on their own when they use pellicles or when they switch from one to the other. Pellicle technology. It will not change the device generation manufactured, so that is both good and bad for us. So there is no hard deadline on the one side and also no pressure on the other side. That is true, but generally, I think it is positive that there is no time-wise killer criterion for when to reach it. But of course, every day you are working with a technology achieving a lower yield. You have a competitive disadvantage because in the device industry at the moment, everything is about manufacturing output, and that is what a yield improvement does. So, I believe those who manage to use CNT technology and finally achieve a better yield have a significant competitive advantage, more profit, and more revenue. And that is what the memory, in particular the GPU and CPU industry, is at the moment all about. So there is a very good business case for better yields.

Unknown 3
43:20 - 44:33

In the risk statements related to the delivery of the second reactor and reactors altogether. You say that there will be a penalty if you do not meet your part of the agreement. The reactor does not perform according to the standards that you have specified in the sales agreement. But based on your discussion now, it seems that is not the case. So the only reason holding up the site acceptance test is that the customer does not have sufficient resources to make it actually productive. So getting it into production signals that there is not such a great hurry to increase production of those pellicles that would be used in the manufacturing process. Or is there any other reason for this to take longer, as it has been almost two years now since you delivered the reactor. So is it just not interesting for the customer to get it up and running because there is no need for the pellicles.

Maximilian Slawinski
44:39 - 46:58

Two years is, of course, a normal timeframe in the semiconductor industry. Depending on what you are talking about, that is even a normal time frame. So when you see, I worked, for example, many years in the silicon carbide industry and the device development in that, which was also fundamentally changed, was typically for a platform development, never lower than three years. The hurry is. So what is the pressure that comes from the imbalance between demand and supply? So there is far more demand in the device industry than supply. And everybody has pressure to increase output. And there are different ways to address that. But for sure, the fastest way to increase supply is improving the yield. But no doubt the semiconductor manufacturing process is extremely sensitive. And along the manufacturing chain, every change, even if it looks tiny, is a risk. This is a risk. And what I can understand is that there are a lot of measures and tests undertaken before implementing a new technology, including the pellicles, because the worst thing. What could happen is if you have even one week of issues with your lithography tool, and in particular with the order book pressure, I can understand the customers being careful. Nevertheless, the. Yes, the third reactor order is a statement from the industry. And when we look at the physics, when we compare it to today's standard material and compounds, it is a big promise for improving yields. In particular, when we reflect on that in relation to the device roadmaps. So we will in the future have far more wafer starts in the area of two nanometer and below, and that will result in higher wattage, higher numerical aperture, and also more layer starts in all aspects. We talk about yield being more critical, the robustness of pellicles being an even more important factor, and also, of course, the manufacturing output in total. So these are promising trends.

Unknown 3
47:01 - 47:16

All right. One of the questions before related to the consumable revenue; I think you said that you didn't record any consumable reactor revenue in the first half. Was that correct?

Mikko Vesterinen
47:17 - 47:18

Not in a significant capacity.

Unknown 3
47:19 - 48:18

Yeah. So basically, even if FST has already one reactor ready to produce, they did not. And therefore, you felt there was no need to deliver more consumables to them. So, does that not also suggest that there is no great hurry to get the production running, even from the first reactor? And of course, you already explained that in the case of the second reactor, there does not seem to be a great hurry to even get the site acceptance test. Or how otherwise would you interpret the situation that the production is not starting in any significant volumes, even from the first customer with whom basically everything has been cleared for production?

Maximilian Slawinski
48:19 - 49:29

Mhm. Of course, what the customers of FST do is only a matter of speculation. But why, for example, is pellicle material buying? Customers are careful in changing a pellicle material due to the sensitivity of the semiconductor device manufacturing supply chain. I think the fact that we received from FST yesterday the second reactor order underlines their confidence and obviously also is related to a forecast from FST requiring a capacity expansion. Otherwise, that reactor order would not have come. And in particular, for the case of FST, I think just yesterday's milestone shows that there is obviously from our customer's point of view more demand inside, as they needed to place a second and a further order, and that it is a matter of time—not so much a question—when the pellicles will be at the device manufacturers, and then also recurring revenues for Canatu will be monetized.

Unknown 3
49:30 - 49:55

All right. In your report, you mentioned that you made some progress in EUV inspection products. What kind of progress did you actually make?

Maximilian Slawinski
49:56 - 50:27

Mhm. So our products today are inspection membranes. We identified in that inspection area opportunities to increase our share of the bill of materials of that total inspection system without being able to disclose too many details. But there are more use cases than only this membrane use case in that area where we can expand the business.

Unknown 3
50:36 - 50:59

All right. And if you say that your testing membranes lasted better or longer in customer use, does that mean that you are also getting a price increase next time you are selling to them because your product has actually proven that it works longer?

Maximilian Slawinski
51:00 - 51:09

We can of course not disclose the price negotiation, but it has definitely proven that the value of what we delivered was higher than anticipated.

Unknown 3
51:10 - 51:44

All right. Now, when you talk about your CAPEX, you limit it to 6 million on an annual basis except for this year. Does that mean that you are not planning to build a new factory? So, you think that the two factories, with the second one ready soon this year, will be enough for your production going forward.

Maximilian Slawinski
51:45 - 52:54

It implies that it is. What we have in manufacturing infrastructure today is sufficient to achieve our 2030 targets. So of course we still have a CAPEX plan. It is not zero. But of course, it is also a consequence of saying that for the Polaris market, we are an equipment business. This is of course having a far lower CAPEX than if you were to manufacture the pellicles in-house. That is one result of that. And yes, the allocation of focusing only on products with a higher euro per square centimeter value has, of course, an impact on the revenue achievable on the manufacturing line. When I say I will only develop and manufacture in our factories products with a high or higher euro per square centimeter value, the achievable revenue with the installed capacity rises. By producing only products with a higher euro per square centimeter value in today's factories, the achievable revenue with installed capacity rises. And that is also a point of that, and a result of not having a demand for extremely high CAPEX in the future over the next four years, let's say.

Unknown 3
52:54 - 53:18

All right. But what does that mean in practice? What part of your production currently has a lower price per square centimeter, and how do you intend to shift production capacity toward higher-value offerings? We don't quite understand that. What is the low value-adding part that you want to discontinue?

Maximilian Slawinski
53:18 - 54:13

We had products on the roadmap which we were in development, which would eat up a lot of capacity without achieving a lot of revenue. So, um. Without going into detailed customer projects, it of course makes a big difference. For example, if you have some square centimeters of a hormone detection sensor, or if you deposit carbon nanotubes on several square meters in markets which are also partly commoditizing, depositing CNTs on extremely large areas without having the visibility that these markets would value that with reasonably high prices. We stopped these projects. But that, of course, was a former manufacturing plan, a part of which would have resulted in more CAPEX.

Unknown 3
54:14 - 54:55

All right. Then finally, you have now downgraded your long-term targets for the second time within a year. And what makes you think that your current estimates for the future would be any more realistic than the two previous ones have been? So why should we now believe that even the numbers that you are showing today, the net sales target of 100 million by 2030, would be realistic and achievable? Because already within a year, you have changed those long-term targets twice.

Mikko Vesterinen
54:58 - 55:52

Yes, I think I would. Regarding the revenue target of reaching 100 million or more, it is very close to what we stated in the spring. Why we made a slight change. It used to be 100 to 150 million. That reflects these changes. What we have done in the strategy is focus on this reactor-based model and these scalable product businesses. So, as we have stated several times and again this time, the long-term potential is unchanged. We don't see that change there. We do not see a significant change in the revenue target.

Maximilian Slawinski
55:52 - 56:01

And what increased our confidence in the plan yesterday is that the reactor order we received came in ahead of schedule.

Unknown 3
56:04 - 56:38

And finally, if you are so confident in the 100 million target in 2030, which is a long time away. Looking forward. Why don't you provide annual revenue targets or a range, just to guide investors and analysts so that the estimates would be even roughly correct? Why can you be so certain of the long term if you are not certain enough to give information to capital markets on the short term?

Mikko Vesterinen
56:40 - 57:35

Well, I think we have been discussing this today as well, that there are things which are not in our control. They depend on our customers and how they go forward. So timing remains a short-term risk. In the long term. We think that the kind of risk in a way is on a substantially lower level. As Maximilian said, it is less of a question of if, but rather when this happens. And that is why we are confident. But we don't want to specify each year exactly how it goes. Because that is not fully in our hands. And also, we need to preserve our negotiation position towards our customers so that we don't set overly explicit targets, which can then be counterproductive.

Unknown 3
57:37 - 58:26

Yeah. But if you give a range for net sales for the short term and make it wide enough, it would include all the possibilities that you must have in the numbers in your business plan. So why is it so difficult to guide the markets? Because I think the benefit of that would be that you wouldn't need to come with a massive profit warning in the middle of the year, just to reset all estimates that have been produced thus far. So I think the policy that you're running now is clearly more harmful to you, as any kind of guidance-giving exercise would be. If the guidance range is wide enough to basically meet all roughly potential outcomes.

Mikko Vesterinen
58:26 - 58:42

Yes, let us be clear: we have not given a profit warning. We provided preliminary information yesterday regarding the profit and the outlook for this year. It was assessed that the results will decline. It was not a profit warning. I want to clarify that.

Unknown 3
58:43 - 59:05

You might say a lot of technical things, but it was actually a profit warning in the true meaning of the case, so that you let the markets know that current estimates are way higher than what you foresee for this year. So regardless of what you call it, it was a really bad profit warning, feedback taken.

Walter Braun
59:08 - 59:43

Walter Rossi from Danske Bank. One additional question about modeling the revenues until 2030. Would you say it still makes sense to try to model it based on the number of reactors sold? Or should we focus more on recurring elements? And roughly what would you say is the split between these reactors, hardware sales, and recurring revenues in 2030.

Maximilian Slawinski
59:47 - 61:03

So the majority of the planned revenues will be recurring. Either they are products or royalties and fees. So it will not be, let's say, driven by reactors. And what is also important is that in this plan until 2030, we have cumulatively sold a minimum of ten reactors. So that means there are seven more to go. This is an exponential curve. And I would be very happy if every time I am 100 days in a company we achieve such a milestone. So this is of course very important. But the model includes having a minimum of ten reactors sold until 2030 and having a majority of non-reactor sales revenue. So what would that mean? We have then, of course, when you are less dependent on reactor sales, less volatility. That is automatically leading to a less volatile revenue trajectory. And with that also, there is easier visibility than you have today. This is pretty clear. It's easier to forecast a product business than an equipment business.

Walter Braun
61:04 - 61:12

Just to make sure I heard correctly. So by 2030, more than 50% of sales would be recurring.

Maximilian Slawinski
61:12 - 61:18

The point would be not reactor business. So a product, or let's say a license, royalty, or fee revenue. Yes.

Walter Braun
61:19 - 61:23

And by the way, is this semiconductors or all?

Maximilian Slawinski
61:23 - 61:25

Overall Canatu in total.

Walter Braun
61:25 - 61:29

Ten reactors in total, including all of these three. Okay. Thank you.

Unknown 1
61:34 - 61:44

I will take one last question. We have now talked at length about your two existing reactor clients. But how is the sales pipeline for new customers developing?

Maximilian Slawinski
61:48 - 64:27

Yeah. Good. The perspective has opened with our decision to say, okay, we are an equipment company. I think that makes Canatu much more attractive. Of course, we are now very interesting in the EUV pellicle market for those who might have seen us before today as potential competitors. So let's say the opportunity widens with that. That is a starting point. And then there is a way to go to have a design-in, design-win, and orders. Sure. But overall, on the potential customer base, in particular for the semiconductor business, that is an improvement. For the RMD business, as the renaming implies, we are not seeing this anymore as a purely automotive business in the long term. As a purely automotive business, automotive is for sure a big market, and it is a market where we have a lot of experience and have already successfully sold products. But in particular, when we talk about the robotics market, that is a very, very promising market for Canatu. Why? Because when you see our solutions, they are part of the solutions we have, which are part of sensing or acting. When you compare us to other tier two and tier one companies, they are also pursuing a new go-to-market strategy with former automotive products. And we are following that logic as well. And also in Europe, the robotics market is distinct from the automotive market and is an organically and strongly growing market. Regarding the automotive market, when you look at the total number of cars, it consistently remains between 80 and 100 million. It is in itself not really strongly growing, which leads to the fact that you have this transformational growth, such as in EVs, where at the moment, you suddenly have a commoditized situation with stronger price competition. And by widening our perspective to robotics and defense, we expect to be positioned in markets that are not as price-sensitive, nor are they on the long run, as they are organically stronger and growing for a much longer period. In particular, the robotics market. When you see the forecast for humanoid robots, relatively optimistic forecasts suggest that in ten years from now, it may be a factor of ten bigger than the number of cars. And when you then see the bill of materials of these robots for sensors, it is almost equal to that of a car. And that is a super interesting market for Canatu.

Unknown 1
64:29 - 64:29

Thank you.

Mikko Vesterinen
64:32 - 64:49

Thank you. I think we are done with time. Thank you for the very good questions. I am just checking all the questions we received online, and most of them were already covered here in the audience. So thank you.

Maximilian Slawinski
64:49 - 64:58

Yes, thank you very much. Also from my side. Let's hope for further success in the future. Thank you for your trust.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…